TI
CASC

Trexquant Investment’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Trexquant Investment’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-16,283
Closed -$70K – 1468
2016
Q4 		$70K Buy
+16,283
New +$105K 0.01% 913

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Trexquant Investment's CASC Position: Q1 2017 in Review

Trexquant Investment sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2017, closing a stake of 16,283 shares — an estimated $70K sold.

Trexquant Investment first reported a position in CASC in Q4 2016 and held it in 1 quarter. The position peaked at $70K in Q4 2016. 78 funds tracked by Wall St. Rank hold CASC as of Q1 2017.

  • Trexquant Investment reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Trexquant Investment sold 16,283 Cascadian Therapeutics, Inc. shares in Q1 2017, an estimated $70K.
  • Trexquant Investment first reported a position in Cascadian Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Trexquant Investment's Cascadian Therapeutics, Inc. position peaked at $70K in Q4 2016.
  • 78 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2017.

Based on Trexquant Investment's 13F filing for Q1 2017, filed 9 May 2017.